AI Article Synopsis
- MicroRNAs (miRNAs) therapy shows promise for treating androgen-independent prostate cancer (AIPC), overcoming the limitations of hormonal therapy.
- The study presents pH/ATP-activated nanocomplexes that enhance the delivery of miR146a, effectively inhibiting the expression of EGFR and suppressing cancer cell behaviors like invasion and growth.
- In vivo experiments indicate that these nanocomplexes significantly reduce tumor volume growth compared to traditional delivery methods, highlighting their potential for AIPC gene therapy.
Article Abstract
MicroRNAs (miRNAs) therapy has shown to have great promise for the treatment of androgen-independent prostate cancer (AIPC) due to the low efficiency of hormonal therapy. However, instability of RNA and inefficiency of RNA therapy limit the use of miRNAs in the treatment of AIPC. Here, we report a pH/ATP-activated nanocomplexes for increasing cytosolic delivery of miR146a which can effectively inhibit the expression of epidermal growth factor receptor (EGFR) in AIPC. The nanocomplexes show identical suppressing effect in invasion, colony formation, migration ability, and growth of DU145 cells compared with Lipofectamine 2000 (lipo). But for in vivo experiments, the nanocomplexes vigorously suppress the growth of tumor volumes comparing to lipo group after five weeks' treatment. These results demonstrate the potential of the pH/ATP-activated nanocarriers for AIPC gene therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acsami.9b21707 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!